Clinical Trial Update: Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 results update for lifileucel (LN-144), autologous tumor-infiltrating lymphocytes, in patients with metastatic melanoma; results from the study have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Lifileucel (autologous tumor-infiltrating lymphocytes (TIL) therapy)

Snippet

Sponsor: Iovance Biotherapeutics, Inc. | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-12-09